A bout one-third of Americans are not getting enough vitamin D, according to a March report from the Centers for Disease Control and Prevention. That conclusion came about 6 months after the Institute of Medicine (IOM) issued new recommendations increasing the dietary reference intakes for vitamin D.
Notably absent from both reports were recommendations regarding vitamin D's relationship to cancer.
For years, some studies have suggested that vitamin D intake is associated with reduced risk of cancer -particularly colorectal cancer but also breast, prostate, and pancreatic cancers. The fi ndings have attracted media attention and raised hope that vitamin D supplements could ward off the disease. But other studies, including some large ones, have had confl icting results ( see sidebar).
As a result, the IOM concluded that the evidence to date is too weak to make recommendations regarding vitamin D and cancer. "The role of vitamin D in both prevention and treatment of cancer remains a work in progress," said IOM committee member JoAnn E. 
The VITAL Trial
Amid the many studies under way is a newly launched, large multicenter trial called VITAL , investigating whether high doses of vitamin D and the omega-3 fatty acids found in fi sh oil can reduce the risk of developing cancer, heart disease, and stroke. Primary outcomes are incidence of these diseases after 5 years.
VITAL is the fi rst large-scale randomized trial designed to test vitamin D's role in preventing cancer and cardiovascular disease, Manson said. The trial is testing a higher dose of vitamin D than most previous studies and is "large enough to provide conclusive results."
In mid-2010, the trial began recruiting 20,000 U.S. men aged 60 years and over and women aged 65 and older, and enrollment will continue through 2011. The basically healthy participants, with no history of cancer or cardiovascular disease, will receive two pills per day in one of the following combinations: vitamin D 3 and fi sh oil, vitamin D 3 and fi sh oil placebo, vitamin D 3 placebo and fi sh oil, or both placebos. (Vitamin D 3 dose is 2,000 IU; fi sh oil dose is 1 g.) They will be monitored for 5 years and will be asked to complete an annual questionnaire about health, lifestyle habits, smoking, medication, and new medical diagnoses. Consent for medical record review will be requested to confi rm health outcomes. (For more information But additional studies may be defi nitive only if they are measuring vitamin D intake in • The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial included a casecontrol study that found no association between vitamin D status and risk of breast cancer ( Cancer Epidemiology, Biomarkers, and Prevention , 2008 "Vitamin treatment may not be effective in these trials because nutrient intake among the participants is already at optimal levels," Morris wrote in an e-mail. "Public health may be better served by initially conducting trials in individuals with insuffi cient levels of the vitamin studied and, if effective, to then test people with adequate levels."
Morris said she is unaware of trials of vitamin D and cancer risk reduction that are restricting eligibility to people with low levels of the vitamin. But she believes that could be an important criterion for patient selection.
"I am in discussion with various experts across multiple fi elds on this topic," Morris said, and she hopes to convene a conference "whose goal would be to come up with more appropriate approaches for examining nutritional relations with disease in both randomized trials and epidemiological studies and to make recommendations for how to establish best evidence in nutritional science."
